Trends in Infective Endocarditis Incidence, Microbiology, and Valve Replacement in the United States From 2000 to 2011  by Pant, Sadip et al.
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y VO L . 6 5 , N O . 1 9 , 2 0 1 5
ª 2 0 1 5 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 5 . 0 3 . 5 1 8Trends in Infective Endocarditis Incidence,
Microbiology, and Valve Replacement in
the United States From 2000 to 2011
Sadip Pant, MD,* Nileshkumar J. Patel, MD,y Abhishek Deshmukh, MD,z Harsh Golwala, MD,* Nilay Patel, MD,x
Apurva Badheka, MD,k Glenn A. Hirsch, MD, MHS,* Jawahar L. Mehta, MD, PHD{ABSTRACTFro
Me
Mi
Ca
Me
lat
Lis
Yo
MaBACKGROUND In accordance with the 2007 American College of Cardiology and American Heart Association infective
endocarditis (IE) guideline update, antibiotic prophylaxis is now being restricted to a smaller number of cardiac conditions
with very high risk for adverse outcomes from IE. However, there is scant data on IE trends since this major practice
change in the United States.
OBJECTIVES The aim of this study was to compare temporal trends in IE incidence, microbiology, and outcomes before
and after the change in the 2007 IE prophylaxis guideline in the United States.
METHODS The NIS (Nationwide Inpatient Sample) database was used to investigate IE hospitalization rates in the
United States from 2000 through 2011. The mean annual rates of IE before and after the 2007 guideline change were
compared using segmented regression analysis.
RESULTS There were 457,052 IE-related hospitalizations in the United States from 2000 to 2011, with a steady increase
in incidence (p < 0.001). The trend in IE hospitalization rates from 2000 to 2007 and from 2008 to 2011 was not
signiﬁcantly different (p ¼ 0.74). The increases in the number of Staphylococcus IE cases per million population during
the study periods 2000 to 2007 and 2008 to 2011 were similar (p ¼ 0.13), but Streptococcus IE hospitalization rates were
signiﬁcantly higher after the release of new guidelines (p ¼ 0.002). Finally, valve replacement rates for IE steadily
increased from 2000 to 2007 (p ¼ 0.03) but showed a plateau from 2007 to 2011. Overall, there was no signiﬁcant
difference in the rates of valve replacement for IE before and after the release of new guideline (p ¼ 0.23).
CONCLUSIONS These results show that IE incidence has increased in the United States over the past decade. With
regard to the microbiology of IE, there has been a signiﬁcant rise in the incidence of Streptococcus IE since the 2007
guideline revisions. However, the rates of hospitalization and valve surgery for IE have not increased since the change in
IE prophylaxis guideline in 2007. (J Am Coll Cardiol 2015;65:2070–6) © 2015 by the American College of Cardiology
Foundation.T he epidemiology of infective endocarditis(IE) has changed over the years because ofchanges in the prevalence of risk factors, as
well as improved diagnostic tools and management.
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2071device implants, also contributes to increasing IE
incidence. Finally, global trends in infectious disease
epidemiology also may affect trends in IE. A revised
guideline for antibiotic prophylaxis for the preven-
tion of IE was released in 2007 by the American Heart
Association (AHA) and the American College of Cardi-
ology (ACC) (6). According to the new guidelines,
antibiotic prophylaxis is restricted to only a small
number of cardiac conditions with high risk for
adverse outcomes from IE. However, there is a
paucity of data on IE trends since this major change
in practice guidelines in the United States.SEE PAGE 2077Through our study, we sought to: 1) identify trends
in the incidence of IE before and after the publication
of the new guideline for antibiotic prophylaxis for IE
in 2007; 2) assess trends in the microbiology of IE over
the past decade; and 3) assess the trend in valve
replacement before and after the change in the
guideline.
METHODS
DESIGN. We performed a retrospective observational
cohort study, using the Healthcare Cost and Utiliza-
tion Project NIS (Nationwide Inpatient Sample)
database, sponsored by the Agency for Healthcare
Research and Quality (7). We used the International
Classiﬁcation of Diseases, Ninth Revision, Clinical
Modiﬁcation code to identify patients discharged
with acute and subacute bacterial endocarditis
between 2000 and 2011 (Online Appendix). Simi-
larly, the microbiology, as well as valve replace-
ment, were identiﬁed using appropriate procedureTABLE 1 Incidence of IE, Microbiology, and Valve Replacement From
Year
Total No.
of IE Cases
Incidence of
IE per 100,000
Population
Valve Replacement
per 1,000
IE Cases
Staph
per
Po
2000 29,820 11 14
2001 31,526 11 16
2002 32,229 11 19
2003 35,190 12 18
2004 36,660 13 19
2005 37,508 13 23
2006 40,573 14 23
2007 38,207 12 30
2008 41,143 14 19
2009 43,502 14 27
2010 43,560 14 27
2011 47,134 15 26
IE ¼ infective endocarditis.codes. With regard to microbiology, 4 groups
were included: Staphylococcus, Strepto-
coccus, Gram negative (GN), and fungi. We
excluded endocarditis due to syphilis, rheu-
matic heart disease (without infection),
gonococcal endocarditis, and lupus or other
noninfectious causes. We used weights pro-
vided with the NIS to generate national
estimates.STUDY POPULATION. The NIS database is the largest
all-payer database (Medicare, Medicaid, private in-
surance, and uninsured) of hospital inpatient stays
available in United States (excluding the federal,
institutional, and short-term rehabilitation hos-
pitals). Each year, the NIS data are updated to
approximately represent a 20% stratiﬁed sample of
U.S. hospitals. Each individual hospitalization is
deidentiﬁed and maintained in the NIS as a unique
entry with 1 primary discharge diagnosis and #24
secondary diagnoses during that hospitalization.
Each entry also contains information on demographic
details, including age, sex, race, insurance status,
primary and secondary procedures (up to 14), hospi-
talization outcome, total charges, and length of stay.
Data from the NIS have been previously used to
identify, track, and analyze national trends in health
care utilization, patterns of major procedures, trends
in hospitalizations, charges, quality, and outcomes
(8–10). They also have been used to study the
epidemiology of IE in the United States in the past
(11,12).
STATISTICAL ANALYSIS. We used Stata IC version
11.0 (StataCorp LP, College Station, Texas) and SAS
version 9.2 (SAS Institute Inc., Cary, North Carolina)2000 to 2011
ylococcal IE
1 Million
pulation
Streptococcal
IE per 1 Million
Population
Gram-Negative
IE per 1 Million
Population
Fungal
IE per 10 Million
Population
35 26 6 6
38 28 5 11
38 29 6 11
42 29 7 12
46 29 7 11
46 31 8 15
50 32 8 14
46 32 8 17
51 35 8 17
57 38 12 16
55 38 12 17
61 42 12 20
FIGURE 1 Trend in the Incidence of IE Hospitalization in the United States
(per 100,000 Population) From 2000 to 2011
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2000 2002
Change in the incidence of IE for year 2000-2007     [0.54 (0.32 to 0.75), p<0.001]
Change in the incidence of IE for year 2007-2011       [0.60 (0.23 to 0.97), p=0.005]
Change of slope between 2000-2007 & 2007-2011  [0.06 (–0.36 to 0.49), p=0.74]
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Relative change in the incidence of infective endocarditis (IE) cases is shown for 2000 to
2007 and for 2007 to 2011.
FIGURE 2 Trends in IE Microbiology as a Percent of Total IE Cases From 2000 to 2011
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Note that the increasing incidence of infective endocarditis (IE) from 2000 to 2011 was
seen across all 4 pathogens associated with IE, namely, Staphylococcus, Streptococcus,
Gram-negative bacteria, and fungi.
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2072for the analyses, which accounted for the com-
plex survey design and clustering. To estimate the
annual rates of IE hospitalizations, we divided the
total number of IE cases in a given year by the
U.S. census population for that year, which were
represented in tables and graphs per 100,000 or per
million population. The proportion of IE hospitali-
zations due to each organism was expressed in
2 ways: 1) as a proportion of all IE hospitalizations;
and 2) per population for that year. We compared
the estimated mean annual rates of IE for data from
before and after the introduction of the 2007 ACC/
AHA IE antibiotic prophylaxis guidelines using
piecewise regression analysis (also known as seg-
mented regression analysis) of the interrupted time
series (13). The statistical signiﬁcance level was set
at p # 0.05.
RESULTS
A total of 457,052 estimated IE hospitalizations were
identiﬁed during the study period (2000 to 2011). The
annual IE hospitalization rate, microbiology, and
valve replacement rates in the United States from
2000 to 2011 are summarized in Table 1.
In the entire cohort, there was a steady increase in
the incidence of IE hospitalizations from 2000 to 2011
(p < 0.001). The change in IE hospitalization rate for
2000 to 2007 was 0.54 per 100,000 population (95%
conﬁdence interval: 0.32 to 0.75; p < 0.001). The
change in IE hospitalization rate for 2007 to 2011 was
0.6 per 100,000 population (95% conﬁdence interval:
0.23 to 0.97; p ¼ 0.005). The trends in IE hospitali-
zation rates per 100,000 population between the
study periods 2000 to 2007 and 2008 to 2011 were not
signiﬁcantly different (p ¼ 0.74) in the United States
(Figure 1).
The microbiology data demonstrated a steady rise
in number of Staphylococcus IE cases. The proportion
of IE due to Staphylococcus (expressed as percentage
of total IE cases) increased from 33% in 2000 to 40%
in 2011, a relative increase of 18.9% (p < 0.001)
(Figure 2). The proportion of IE due to Streptococcus
also increased from 24.8% in 2000 to 27% in 2011, a
relative increase of 10.6% (p < 0.001) (Figure 2).
During the study period, the proportion of IE due to
GN bacteria increased from 5.3% to 8.2% (a relative
increment of 33.9%; p < 0.001), and IE due to fungi
increased from 0.6% to 1.4% (a relative increment of
59.6%; p < 0.001).
The increases in the number of Staphylococcus IE
cases per million population during the study period
2000 to 2007 and 2008 to 2011 were similar (p ¼ 0.13)
(Central Illustration). There was, however, a
CENTRAL ILLUSTRATION IE and 2007 Guidelines: Trend in the Incidence of Staphylococcus and Streptococcus IE
Pant, S. et al. J Am Coll Cardiol. 2015; 65(19):2070–6.
The infective endocarditis (IE) trends are assessed (per 1 million population) in the United States from 2000 to 2011. Note that the slope for
Streptococcus (Strep) IE is signiﬁcant between 2000 and 2007 and between 2007 to 2011 but not for Staphylococcus (Staph) IE.
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2073statistically signiﬁcant increase in Streptococcus IE
cases comparing the time periods before (2000 to
2007) and after (2008 to 2011) the release of new
guidelines (p ¼ 0.002) (Central Illustration).
The valve replacement rates for IE steadily
increased from 2000 to 2007 (p ¼ 0.03), followed
by a plateau from 2007 to 2011. There was nosigniﬁcant difference in valve replacement rates for
IE in the United States after the inception of the
2007 guideline (p ¼ 0.23) (Figure 3). The trends in
valve replacement for Staphylococcus IE and Strep-
tococcus IE did not change signiﬁcantly before and
after 2007 (p ¼ 0.13 and p ¼ 0.49, respectively)
(Figure 4).
FIGURE 3 Valve Replacement Rates for IE (per 1,000 IE Cases) in the United States
From 2000 to 2011
0
2000 2002
Change in no. of valve replacement for 2000-2007          [1.46 (0.14-2.79), p=0.03]
Change in number of valve replacement for 2007-2011    [–1.30(–2.21-2.21), p=1.00]
Change in the slope between 2000-2007 & 2007-2011   [–1.46(–4.04-1.11), p=0.23]
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Although the rates for valve replacement increased from 2000 to 2007, rates since
then have remained constant. IE ¼ infective endocarditis; Staph ¼ Staphylococcus;
Strep ¼ Streptococcus.
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2074DISCUSSION
Our study has several important ﬁndings. First, there
has been a steady increase in the incidence of IE
hospitalizations over the past decade in the United
States. However, the incidence of IE pre- and post-
inception of new antibiotic prophylaxis guidelines
is not signiﬁcantly different (Central Illustration).
In parallel to these ﬁndings, the rate of valve
replacement for IE did not change after the release of
new guidelines in 2007. Second, the increase in IE
incidence was seen across all types of pathogens:
Staphylococcus, Streptococcus, GN bacteria, and fungi.
Finally, the rate of Streptococcus IE–related hospital-
ization increased signiﬁcantly after the release of new
guideline in the United States, while Staphylococcus
IE hospitalizations, although also on the rise, did not
differ signiﬁcantly after the 2007 ACC/AHA guideline
update.
The increase in the U.S. incidence of IE over the
past decade has been reported previously and is
likely related to an increase in the sizes of at-risk
populations, such as older, diabetic, and hemodialy-
sis patients (14,15). In addition, the number of inva-
sive procedures leading to transient bacteremia has
increased markedly over this time period (2). Finally,
there has been increase in survival in IE risk–prone
populations, such as adults with congenital heart
disease and prosthetic device implants, leading toan increase in IE incidence. Despite the overall in-
crease in IE hospitalizations from 2000 to 2011, we
did not observe any signiﬁcant change in hospitali-
zation rates from the pre-guideline era (2000 to
2007) to the post-guideline era (2007–2011). Similar
ﬁndings have been replicated in France, where a
guideline change in 2002 did not result in an in-
crease in IE cases (16). However, a recent study
from the United Kingdom showed an increase in IE
cases with a decrease in antibiotic use, after a Na-
tional Institute for Health and Care Excellence
guideline change in 2008 (17). We speculate that
the difference in microbiology of IE among these
populations may partly account for such differ-
ences. Staphylococcus has remained the predomi-
nant pathogen for IE in the United States. Because
the antibiotic prophylaxis in the guideline does not
routinely cover Staphylococcus, its growing trend
since 2000 would not be affected by the change in
the 2007 guideline.
Our study shows that Streptococcus IE cases
increased signiﬁcantly after the change in the guide-
line in 2007. This is in contrast to prior studies, which
showed no inﬂection in hospitalization rates after
the 2007 ACC/AHA changes in prophylaxis recom-
mendations (11,12). The prior studies, however, had
limited follow-up duration (2-year follow-up after the
guideline change). A similar observation was made
in the U.K. study, in which a steady incidence of IE
was noted for ﬁrst 2 years after publication of the
guidelines (18).
The increasing incidence of IE from 2000 to 2011
was seen across all 4 pathogens associated with IE,
namely, Staphylococcus, Streptococcus, GN bacteria,
and fungi. Speciﬁcally, the number of staphylococcal
IE cases increased, with a 20% relative rise during
the 11-year study period. Staphylococcus has been
found to be a predominant etiology for health care–
associated native valve IE in the United States for
nosocomial as well as nonnosocomial acquisition
(2). Increased contact with health care providers, an
increase in invasive procedures associated with
bacteremia, and increases in the sizes of high-risk
population, such as the elderly and patients with
diabetes mellitus or end-stage renal disease, may
well be responsible for growing rates of staphylo-
coccal IE cases (2,3,5,19). In addition, there has been
an increasing trend in the use of prosthetic cardiac
devices (pacemakers, deﬁbrillators, and prosthetic
cardiac valves) in the United States (20), which make
patients susceptible to staphylococcal infections.
However, the rates of rise in Staphylococcus IE
before and after the guideline change did not differ
signiﬁcantly.
FIGURE 4 Trend in Valve Replacement for Staphylococcus Endocarditis
(per 1,000 Total IE Cases) and Streptococcus Endocarditis (per 1,000 Total
IE Cases) in the United States From 2000 to 2011
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Change in valve replacement in staph IE for year 2000-2007, [1.57 (0.62 to 2.53), p=0.005]
Change in valve replacement in Staph IE for year 2007-2012, [0.20 (–1.40 to 1.80), p=0.78] 
Change in slope between 2000-2007 & 2007-2011, [–1.37 (–3.23 to 0.49), p=0.13]
Change in valve replacement in Strep IE for year 2000-2007, [1.32 (–1.14 to 3.78), p=0.10]
Change in valve replacement in Strep IE for year 2007-2012, [–0.20 (–4.32 to 3.92), p=0.12]
Change in slope between 2000-2007 & 2007-2011, [–1.52 (–6.32 to 3.27), p=0.49]
The rate of valve replacement for Streptococcus endocarditis did not change signiﬁcantly,
but that for Staphylococcus endocarditis increased signiﬁcantly from 2000 to 2007 and
then stabilized. IE ¼ infective endocarditis.
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2075We also found that the overall rates of valve
replacement for IE in the United States have stabi-
lized since 2007. This was observed for both Strepto-
coccus and Staphylococcus IE. This may reﬂect the
increasing awareness of this disease and better diag-
nostic tools, leading to earlier detection of IE in the
United States. As a result, fewer patients may be
developing severe complications from this disease
that require surgical intervention. This is supported
by our study, in which we noticed that rates of valve
replacement for Staphylococcus IE changed signiﬁ-
cantly before 2007 (p ¼ 0.05). However, the trend
stabilized after 2007 (p ¼ 0.78) (Figure 3).
STUDY LIMITATIONS. Despite its national scope and
the use of a widely used, well-characterized data-
base, our study had some important limitations. The
main one is the lack of proper validation studies for
the International Classiﬁcation of Diseases codes for
IE. However, there has been a pilot study with a
broader extraction of these codes for IE, which had a
positive predictive value of 81% (21). The trend data
also are affected by variations in coding practices
among hospitals. Hence, it is not possible to know
whether the increase in the incidence of Strepto-
coccus IE is due to more complete recording or a true
increase. However, there was no unexpected increase
seen in IE due to Staphylococcus, GN bacteria, or
fungi, which at least points toward the latter specu-
lation that this observation might be something more
than just a coding issue. Furthermore, the NIS, being
a discharge-level database, cannot distinguish if
multiple hospitalizations are from the same patient.
This may limit the precision of our estimates. Finally,
our database does not capture antibiotic use, and
hence, we do not know the impact of the 2007
guideline change on antibiotic prescription for IE
prophylaxis. Despite these limitations, the NIS data-
base provides data from approximately 20% of all
U.S. community hospitals. This large cohort, repre-
sentative sample, and longer follow-up duration after
the 2007 guideline change makes our study reﬂective
of changing trends in IE hospitalizations from a na-
tional perspective.
CONCLUSIONS
The overall incidence of IE showed a steady increase
in the United States from 2007 to 2011. However, the
annual hospitalization rates and frequency of valve
surgery due to IE have not changed signiﬁcantly
since the change in IE prophylaxis guideline in 2007.
With regard to the microbiology of IE, there has
been a signiﬁcant rise in the incidence of Strepto-
coccus IE since the 2007 guideline revisions. Wespeculate that this could be related to the decrease
in the use of IE antibiotic prophylaxis since the
guideline change. A prospective study designed to
understand the antibiotic prescription pattern after
the change in IE guidelines is needed to further test
the validity of our observations. Furthermore, on-
going monitoring of the impact of these guideline
recommendations is highly warranted, as the new
guideline in itself is not “evidence based” but rather
attempts to demonstrate the lack of evidence un-
derlying the previous recommendations for IE pro-
phylactic antibiotics.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Unnec-
essary use of antibiotic drugs exposes patients to un-
necessary side effects and leads to the development
antibiotic-resistant bacteria.
COMPETENCY IN PATIENT CARE: Since the publica-
tion of the 2007 ACC/AHA scientiﬁc statement on IE,
antibiotic prophylaxis is recommended for a more
restricted number of cardiac conditions in which IE is
associated with a high risk for adverse outcomes.
TRANSLATIONAL OUTLOOK: More research is
needed to deﬁne the conditions for which antibiotic
prophylaxis is actually effective in preventing IE and to
assess the impact of changes in the practice of antibiotic
prophylaxis on the epidemiology of IE.
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